Mariella Simon

Mariella Simon

Auto-generated profile, based on publicly available information

Mariella Simon

Division of Metabolic Disorders, Rady’s Children’s Health Orange County, Orange, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2011 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CKChristopher J Klein
Christopher J Klein
MBMaria-Victoria Botuyan
Maria-Victoria Botuyan
YWYanhong Wu
Yanhong Wu
CWChristopher J. Ward
Christopher J. Ward
GNGarth A Nicholson
Garth A Nicholson
PDPeter J Dyck
Peter J Dyck
Christopher Klein and colleagues report that DNMT1 is disrupted in hereditary sensory neuropathy with dementia and hearing loss. The mutations lead to reduced methyltransferase activity, leading to global hypomethylation and site-specific hypermethylation. DNA methyltransferase 1 (DNMT1) is crucial for maintenance of methylation, gene regulation and chromatin stability1,2,3. DNA mismatch repair, cell cycle regulation in post-mitotic neurons4,5 and neurogenesis6 are influenced by DNA methylation. Here we show that mutations in DNMT1 cause both central and peripheral neurodegeneration in one form of hereditary sensory and autonomic neuropathy with dementia and hearing loss7,8. Exome sequencing led to the identification of DNMT1 mutation c.1484A>G (p.Tyr495Cys) in two American kindreds and one Japanese kindred and a triple nucleotide change, c.1470–1472TCC>ATA (p.Asp490Glu–Pro491Tyr), in one European kindred. All mutations are within the targeting-sequence domain of DNMT1. These mutations cause premature degradation of mutant proteins, reduced methyltransferase activity and impaired heterochromatin binding during the G2 cell cycle phase leading to global hypomethylation and site-specific hypermethylation. Our study shows that DNMT1 mutations cause the aberrant methylation implicated in complex pathogenesis. The discovered DNMT1 mutations provide a new framework for the study of neurodegenerative diseases.

1 November 1995 in Neuron
Verified
Journal Article
Closed access
JAJayashree Aiyar
Jayashree Aiyar
JWJane M. Withka
Jane M. Withka
JRJames P. Rizzi
James P. Rizzi
DSDavid H. Singleton
David H. Singleton
GAGlenn C. Andrews
Glenn C. Andrews
KCK. George Chandy
K. George Chandy

1 May 2003 in Neuromuscular Disorders
Verified
Journal Article
Closed access
SWSara T Winokur
Sara T Winokur
KBKathy Barrett
Kathy Barrett
JMJorge H Martin
Jorge H Martin
JFJames R Forrester
James R Forrester
MSMariella Simon
Mariella Simon
DFDenise A Figlewicz
Denise A Figlewicz

18 April 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
FJFuyun Ji
Fuyun Ji
MSMark S. Sharpley
Mark S. Sharpley
ODOlga Derbeneva
Olga Derbeneva
LALeonardo Scherer Alves
Leonardo Scherer Alves
PQPin Qian
Pin Qian
DWDouglas C C. Wallace
Douglas C C. Wallace
The distinction between mild pathogenic mtDNA mutations and population polymorphisms can be ambiguous because both are homoplasmic, alter conserved functions, and correlate with disease. One possible explanation for this ambiguity is that the same variant may have different consequences in different contexts. The NADH dehydrogenase subunit 1 (ND1) nucleotide 3394 T > C (Y30H) variant is such a case. This variant has been associated with Leber hereditary optic neuropathy and it reduces complex I activity and cellular respiration between 7% and 28% on the Asian B4c and F1 haplogroup backgrounds. However, complex I activity between B4c and F1 mtDNAs, which harbor the common 3394T allele, can also differ by 30%. In Asia, the 3394C variant is most commonly associated with the M9 haplogroup, which is rare at low elevations but increases in frequency with elevation to an average of 25% of the Tibetan mtDNAs (odds ratio = 23.7). In high-altitude Tibetan and Indian populations, the 3394C variant occurs on five different macrohaplogroup M haplogroup backgrounds and is enriched on the M9 background in Tibet and the C4a4 background on the Indian Deccan Plateau (odds ratio = 21.9). When present on the M9 background, the 3394C variant is associated with a complex I activity that is equal to or higher than that of the 3394T variant on the B4c and F1 backgrounds. Hence, the 3394C variant can either be deleterious or beneficial depending on its haplogroup and environmental context. Thus, this mtDNA variant fulfills the criteria for a common variant that predisposes to a “complex” disease.

1 September 2016 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
ASAshlee R. Stiles
Ashlee R. Stiles
MSMariella T. Simon
Mariella T. Simon
ASAlexander Stover
Alexander Stover
SEShaya Eftekharian
Shaya Eftekharian
NKNegar Khanlou
Negar Khanlou
JAJose E Abdenur
Jose E Abdenur

25 March 2015 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
MSMariella Simon
Mariella Simon
ERElodie M Richard
Elodie M Richard
XWXinjian Wang
Xinjian Wang
MOHSIN SHAHZADMOHSIN SHAHZAD
MOHSIN SHAHZAD
VHVincent H Huang
Vincent H Huang
SRSaima Riazuddin
Saima Riazuddin
Here we demonstrate association of variants in the mitochondrial asparaginyl-tRNA synthetase NARS2 with human hearing loss and Leigh syndrome. A homozygous missense mutation ([c.637G>T; p.Val213Phe]) is the underlying cause of nonsyndromic hearing loss (DFNB94) and compound heterozygous mutations ([c.969T>A; p.Tyr323*] + [c.1142A>G; p.Asn381Ser]) result in mitochondrial respiratory chain deficiency and Leigh syndrome, which is a neurodegenerative disease characterized by symmetric, bilateral lesions in the basal ganglia, thalamus, and brain stem. The severity of the genetic lesions and their effects on NARS2 protein structure cosegregate with the phenotype. A hypothetical truncated NARS2 protein, secondary to the Leigh syndrome mutation p.Tyr323* is not detectable and p.Asn381Ser further decreases NARS2 protein levels in patient fibroblasts. p.Asn381Ser also disrupts dimerization of NARS2, while the hearing loss p.Val213Phe variant has no effect on NARS2 oligomerization. Additionally we demonstrate decreased steady-state levels of mt-tRNAAsn in fibroblasts from the Leigh syndrome patients. In these cells we show that a decrease in oxygen consumption rates (OCR) and electron transport chain (ETC) activity can be rescued by overexpression of wild type NARS2. However, overexpression of the hearing loss associated p.Val213Phe mutant protein in these fibroblasts cannot complement the OCR and ETC defects. Our findings establish lesions in NARS2 as a new cause for nonsyndromic hearing loss and Leigh syndrome. Mitochondrial respiratory chain (MRC) disease represents a large and heterogeneous group of energy deficiency disorders. Here we report three mutations in NARS2, a mitochondrial asparaginyl-tRNA synthetase, associated with non-syndromic hearing loss (NSHL) and Leigh syndrome in two independent families. Located in the predicted catalytic domain of the protein, missense mutation p.(Val213Phe) results in NSHL (DFNB94) while compound heterozygous mutation (p.Tyr323*; p.Asn381Ser) is leading to Leigh syndrome with auditory neuropathy. In vivo analysis deemed p.Tyr323* mutant protein to be unstable. Co-immunoprecipitation assays show that p.Asn381Ser mutant disrupts the dimerization ability of NARS2. Leigh syndrome patient fibroblasts exhibit a decreased steady-state level of mt-tRNAAsn. In addition, in these cells, the mitochondrial respiratory chain is deficient, including significantly decreased oxygen consumption rates and electron transport chain activities. These functions can be partially restored with over-expression of wild-type NARS2 but not with p.Val213Phe mutant protein. Our study provides new insights into the genes that are necessary for the function of brain and inner ear sensory cells in humans.